Postmenopausal hormone Rx may cut risk for glaucoma

Postmenopausal hormone rx may cut risk for glaucoma

(HealthDay)—Use of estrogen-only postmenopausal hormone (PMH) treatment may help reduce the risk for primary open-angle glaucoma (POAG), according to research published online Jan. 30 in JAMA Ophthalmology.

Paula Anne Newman-Casey, M.D., from University of Michigan in Ann Arbor, and colleagues retrospectively reviewed claims data from 152,163 women 50 years or older enrolled in a U.S. managed-care plan for at least four years and with at least two visits to an eye care provider during the period 2001 through 2009. Outpatient pharmacy claims were used to identify use of PMH medications.

The researchers found that 1.9 percent of enrollees developed POAG. Each additional month of use of PMH containing estrogen only was associated with a 0.4 percent reduced risk for POAG (hazard ratio [HR], 0.996; P = 0.02), after adjustment for other confounding factors. Each additional month of use of estrogen + progesterone (HR, 0.994; P = 0.08) or + androgen (HR, 0.999; P = 0.89) did not affect risk for POAG.

"If prospective studies confirm the findings of this analysis, novel treatments for this sight-threatening condition may follow," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

VTE risk varies by hormone therapy formulation

Sep 18, 2012

(HealthDay)—The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral ...

Study links genes to common forms of glaucoma

Apr 26, 2012

Results from the largest genetic study of glaucoma, a leading cause of blindness and vision loss worldwide, showed that two genetic variations are associated with primary open angle glaucoma (POAG), a common form of the disease. ...

Body weight and glaucoma risk; new 'map' for severe myopia

Aug 02, 2010

This month's Ophthalmology journal includes surprising research from the Massachusetts Eye and Ear Infirmary on the relation of body weight to the risk for glaucoma. Also, from researchers at the Tokyo Medical and Dental ...

Recommended for you

Multidose eye drop approach approved by joint commission

Dec 14, 2014

(HealthDay)—A policy and procedural approach to the use of multidose eye drops has been approved by The Joint Commission and can reduce costs for patients and facilities, according to an article published ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.